U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, March 9, 2020 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA... Biopharmaceuticals, Oncology, FDA Mylan, Biocon, biosimilar, Avastin, bevacizumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news